Cipher Pharmaceuticals (TSE:CPH) Share Price Passes Above 50 Day Moving Average – Should You Sell?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) shares crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$16.57 and traded as high as C$16.66. Cipher Pharmaceuticals shares last traded at C$16.46, with a volume of 26,094 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group set a C$17.00 price target on shares of Cipher Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of C$17.00.

Cipher Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.32, a current ratio of 1.25 and a quick ratio of 2.67. The company has a market capitalization of C$417.94 million, a price-to-earnings ratio of 13.83 and a beta of 1.15. The firm’s fifty day simple moving average is C$16.57 and its 200 day simple moving average is C$16.50.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last posted its quarterly earnings data on Thursday, May 7th. The company reported C$0.33 EPS for the quarter. The firm had revenue of C$17.39 million during the quarter. Cipher Pharmaceuticals had a net margin of 60.82% and a return on equity of 25.69%. On average, sell-side analysts forecast that Cipher Pharmaceuticals Inc. will post 1.2907348 EPS for the current year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.